Discover MabDesign

MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.
carl-newton-2C6kAtCXf6U-unsplash

Access our network

Join the MabDesign network to take advantage of all the advantages and opportunities offered.
casey-horner-9vf1uj6i6Ww-unsplash

Develop your skills

Consult and register for our next training courses in order to acquire new expertise.
smartworks-coworking-Uz8THWPXwhI-unsplash

Explore our business services

The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.
arlington-research-kN_kViDchA0-unsplash

Upcoming events

Add your title here

16
May.
16 & 17 mai 2024
Other Events
17
May.
17 May, 2024
Mabdesign Event
20
Jun.
June, 20-21, 2024
Mabdesign Event
17
Sep.
17-19 September 2024
Partner Event
25
Sep.
September 25-26 2024
Mabdesign Event

Our News

1648045790625

AGS Therapeutics Strengthens its Patent Portfolio on MicroalgaeExtracellular Vesicles (MEVs) with an International PatentApplication on the use of MEVs to deliver biological agents to thebrain by the intranasal route of administration.

AGS Therapeutics, a preclinical-stage biotech company pioneering microalgae extracellular vesicles (MEV) as a new, universal delivery system, announced the recent publication of its PCT International Application No. PCT/EP2023/078634 – Publication - WO 2024/088808, titled Extracellular Vesicles from Microalgae, their Biodistribution upon Intranasal Administration, and Uses Thereof.
LoValTech

Lovaltech announces the closing of a €6.8 million seed financing round for clinical trials of its first nasal vaccine against COVID-19

Lovaltech announces the closing of a €6.8 million seed financing round for clinical trials of its first nasal vaccine against COVID-19
CREAPHARM GROUP

Myonex closes Creapharm acquisition expanding global services

Myonex has completed the previously announced acquisition of CREAPHARM’s pharmaceutical services business .
pierre-fabre

Pierre Fabre's vibegron gains CHMP positive opinion for OAB

The opinion is a significant step for towards marketing authorisation from the European Commission.

OUR BOARD OF DIRECTORS